Evidence Hub

Broad-Spectrum Antimicrobial Activity of a Ruthenium(II) Polypyridyl Complex against Multidrug-Resistant Uropathogens and Biofilms

James B, Fairbanks SD, Horton M, Thomas JA, McLean S, Varney AM

ACS omega, 2026

Abstract

Antimicrobial resistance and biofilm persistence are major barriers to treating device-associated infections, including catheter-associated urinary tract infections. We evaluated KLS-116, a ruthenium-(II) polypyridyl complex, as a next-generation antimicrobial with broad activity against multidrug-resistant uropathogens. KLS-116 showed potent bactericidal effects under physiologically relevant conditions, with minimum inhibitory concentrations ≤ 25 μM (41.8 mg/L) across diverse species. Checkerboard assays demonstrated compatibility with standard antibiotics, yielding indifferent or additive interactions and no antagonism. Importantly, KLS-116 reduced mature biofilms in continuous-flow catheter models and in static models achieved complete clearance at ≥16× MIC after 24 h, outperforming colistin with prolonged exposure. Over 42 days, resistance evolution showed minimal sensitivity shifts, contrasting with rapid ciprofloxacin resistance, indicating a low propensity for resistance. Activity varied with pH, suggesting that the metabolic state influences efficacy. These results position KLS-116 as a promising candidate for CAUTI management and other biofilm-driven infections, guiding future delivery optimization and in vivo validation.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free